• We have performed about 60 indirect treatment comparisons and network meta-analyses in a wide range of indications since 2006.
  
• We have published network meta-analysis methods for survival outcomes that are based on all the available information captured with the published survival curves.
  
• We are now extending our expertise in network meta-analysis using patient level data in combination with published study level data to improve the validity of indirect comparisons.
  
• We are a leading member of the ISPOR taskforce on indirect treatment comparisons and are currently chairing the development of a checklist to help decision-makers understand and use NMA in their decisions.
  
• We lecture in academic settings and provide short courses at scientific conferences.
  
• We have just completed a series of in-house workshops with European clients as well as a breakfast meeting open to all clients in Paris on April 6. These were all moderated by Jeroen Jansen, our Boston based VP, and leader of our NMA expertise worldwide.
  
• Our specialists will be more than happy to plan a workshop just for you and your team, wherever your location is.
  
  Please feel free to contact Jeroen Jansen jjansen@mapigroup.com in North America or Gert Bergman gbergman@mapigroup.com in Europe or Jean-Pierre Dreyfus, our Business Development Director jpdreyfus@mapigroup.com.

Barbosa CD, Balp MM, Kulich K, Germain N, Rofail D. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence. 2012;6:39-48.

Cope S, Capkun-Niggli G, Gale R, Lassen C, Owen R, Ouwens M, Bergman G, Jansen JP. Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: A patient level mixed treatment comparison. Value in Health (in press)

Delforge M, Dhawan R, Robinson D, Meunier J, Regnault A, Esseltine DL, Cakana A,  van de Velde H, Richardson PG, San Miguel JF. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP versus MP: Results from the VISTA trial. Eur J Haematol (in press)

Guillemin I, Begley C, Chalmers R, Baudouin C. Appraisal of Patient-Reported Outcome Instruments Available for Randomized Clinical Trials in Dry Eye: Revisiting the Standards. Ocular Surface. 2012. Epub 2012 Jan 27

Guyot P, Ades AE, Ouwens MJNM, Welton NJ; Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves; BMC Med Res Methodol. 2012;12:9

Jansen JP, Schmid CH, Salanti G. Direct Acyclic graphs can help understand bias in indirect and mixed treatment comparisons. J Clin Epidemiology (in press)

Marant C, et al. Long-term treatment acceptance: what is it, and how can it be assessed? The Patient: Patient-Centred Outcomes Research (in press)

Matlaga BR, Jansen JP, Meckley LM, Byrne TW, Lingeman JE. Treatment of ureteral and renal stones – A systematic review and meta-analysis of randomized controlled trials. J Urology (in press)

Melchior JC, Préaud E, Carles J, et al. Clinical and economic impact of malnutrition per se on the postoperative course of colorectal cancer patients. Clin Nutr (in press)

Stam WB, Jansen JP, Taylor S. Efficacy of etoricoxib, celecoxib, lumiracoxib, non-selective NSAIDs, and acetaminophen in osteoarthritis: A Mixed Treatment Comparison. Open J Rheumatology (in press)